| ≥1 piece |
We are bringing forward a new, natural phyto-estrogen derivative for women suffering from premature, peri-menopausal, and post-menopausal symptoms. The intent with EstroG-100 is to support the reduction of side affects associated with these conditions.
EstroG-100 is a combination of three herbal extracts, which does include our all new, Decursinol-50. We developed the EstroG-100 four years ago and in commercial form EstroG-100 is the fastest growing product in Asia.
Studies were conducted between May 2003 and April 2004 at Samsung Cheil Hospital which is ranked as the top hospital in Korea. We used a placebo-controlled study, double blinded, 3-12 month dosing periods (4-capsules/ day), safety evaluations, with an averages age of 54 (but > 45).
The net results after 3 months of dosing showed an improvement 5x greater than the Placebo group with positive results towards night sweats, hot flashes, vaginal dryness, aching, and even mood swings. Femoral Neck bone density increased 2.2% in the active group. Serum ALP decreased, Serum Osteocalcin decreased in the active group while the placebo group increased in levels. Serum hGH increased in the active group.
After 12 months of treatment there were no significant changes in E2 and FSH, and no significant changes in weight, blood pressure, and total cholesterol (LDL/HDL). BMI was unchanged. There was reduced Serum Triglycerides (TG) by 23% with the active group, and Serum hGH increased in the active group by 268%.
The key patent is applied to a combination of 3 herbal extracts within the body of the formula. We expect EstroG-100 will REPLACE Black Cohosh in the next 12-24 months because EstroG-100 is the real deal.
The products that we will be offering are classified by the FDA as dietary supplements and not drugs. The U.S FDA has not evaluated the effectiveness of any of these supplements and these supplements cannot be represented to diagnose, treat, cure, or prevent any disease. These supplements have been imported into the U.S with FDA and U.S. Customs review at the respective U.S. ports of entry.